|
End-of-day quote
Korea S.E.
20/10/2026
|
5-day change | 1st Jan Change | ||
| 294,000.00 KRW | -3.76% |
|
-11.71% | -32.18% |
| 10-14 | Pharmicell Secures KRW7.4 Billion Supply Deal With Doosan | MT |
| 10-07 | Doosan Business Research Institute announced that it expects to receive KRW 400 million in funding from Doosan Corporation | CI |
Company Valuation: Doosan Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,938,758 | 1,327,149 | 1,489,665 | 3,898,767 | 12,602,701 | 15,214,523 | - | - |
| Change | - | -31.55% | 12.25% | 161.72% | 223.25% | 20.72% | - | - |
| Enterprise Value (EV) 1 | 7,235 | 5,977 | 4,864 | 8,470 | 16,903 | 19,487 | 19,112 | 17,938 |
| Change | - | -17.4% | -18.62% | 74.13% | 99.57% | 15.29% | -1.92% | -6.14% |
| P/E | 9.92x | -2.12x | -4.3x | -20.1x | 186x | 25.5x | 23.3x | 18.1x |
| PBR | 0.74x | 0.63x | 0.98x | 2.66x | 8.53x | 7.96x | 6.55x | 4.86x |
| PEG | - | 0x | 0.1x | 0.5x | -1x | 0x | 2.44x | 0.6x |
| Capitalization / Revenue | 0.14x | 0.08x | 0.08x | 0.22x | 0.64x | 0.7x | 0.61x | 0.53x |
| EV / Revenue | 0.53x | 0.35x | 0.25x | 0.47x | 0.85x | 0.89x | 0.76x | 0.63x |
| EV / EBITDA | 4.6x | 3.41x | 2.27x | 4.78x | 9.03x | 7.41x | 5.9x | 4.52x |
| EV / EBIT | 7.55x | 5.31x | 3.39x | 8.45x | 15.9x | 10.9x | 7.7x | 5.47x |
| EV / FCF | 21.1x | -35.8x | 3.67x | -21x | 41x | 22.7x | 17.8x | 11.6x |
| FCF Yield | 4.74% | -2.79% | 27.2% | -4.75% | 2.44% | 4.4% | 5.63% | 8.61% |
| Dividend per Share 3 | 2,050 | 2,000 | 2,000 | 2,000 | 4,000 | 4,489 | 5,014 | 5,197 |
| Rate of return | 1.74% | 2.41% | 2.13% | 0.78% | 0.51% | 0.42% | 0.47% | 0.49% |
| EPS 3 | 11,890 | -39,123 | -21,823 | -12,715 | 4,194 | 41,996 | 46,012 | 59,036 |
| Distribution rate | 17.2% | -5.11% | -9.16% | -15.7% | 95.4% | 10.7% | 10.9% | 8.8% |
| Net sales 1 | 13,728 | 16,996 | 19,130 | 18,132 | 19,784 | 21,829 | 25,110 | 28,575 |
| EBITDA 1 | 1,571 | 1,751 | 2,141 | 1,771 | 1,871 | 2,629 | 3,239 | 3,969 |
| EBIT 1 | 958.8 | 1,126 | 1,435 | 1,003 | 1,063 | 1,794 | 2,482 | 3,279 |
| Net income 1 | 656.7 | -696.4 | -388.3 | -226.2 | 75.78 | 570.4 | 681.7 | 951.3 |
| Net Debt 1 | 5,297 | 4,649 | 3,374 | 4,571 | 4,300 | 4,272 | 3,898 | 2,724 |
| Reference price 3 | 118,000.00 | 83,100.00 | 93,900.00 | 255,000.00 | 781,000.00 | 1,071,000.00 | 1,071,000.00 | 1,071,000.00 |
| Nbr of stocks (in thousands) | 17,800 | 17,800 | 17,800 | 17,800 | 17,840 | 17,882 | - | - |
| Announcement Date | 11/02/22 | 07/03/23 | 31/01/24 | 24/01/25 | 10/02/26 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.12x | 4.63x | 20.7x | 0.85% | 334B | |
| 34.62x | 5.41x | 29.48x | 1.05% | 169B | |
| 15.57x | 1.19x | 7.69x | 4.73% | 66.25B | |
| 18.22x | 1.69x | 13.69x | 2.99% | 57.07B | |
| 30.68x | 4.3x | 18.22x | 0.43% | 48.43B | |
| 16.23x | 1.65x | 9.41x | 2.67% | 40.84B | |
| 11.17x | 1.05x | 10.49x | 4.68% | 34.84B | |
| 31.5x | 4.58x | 18.26x | 1.59% | 30.15B | |
| 12.35x | 0.41x | 4.18x | 3.98% | 26.08B | |
| Average | 21.94x | 2.77x | 14.68x | 2.55% | 89.59B | |
| Weighted average by Cap. | 25.77x | 3.84x | 19.19x | 1.72% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- A000150 Stock
- A000157 Stock
- Valuation Doosan Corporation
Select your edition
All financial news and data tailored to specific country editions
